A pharmacokinetic trial with BHV-5000.
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2017
At a glance
- Drugs BHV 5000 (Primary)
- Indications Neurological disorders; Rett syndrome
- Focus Pharmacokinetics
- 14 Nov 2017 Accordign to a Biohaven Pharmaceuticals media release, the company is on track to submit an IND by the end of 2017.
- 23 Jun 2017 New trial record
- 16 Jun 2017 Accordign to a Biohaven Pharmaceuticals media release, this phase 1 pharmacokinetic trial of BHV-5000 is expected to commence in in the second half of 2017.